Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma
- DOI
- 10.1016/j.annonc.2024.08.2338
- Published
- 2024-12
- Container
- Annals of Oncology
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.annonc.2024.08.2338,
title = {Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma},
author = {N. Agarwal and J. Brugarolas and P. Ghatalia and S. George and J.B. Haanen and H. Gurney and R. Ravilla and A. Van der Veldt and B. Beuselinck and I. Pokataev and B.B.M. Suelmann and M.H. Tuthill and D. Vaena and F. Zagouri and J. Wu and R.F. Perini and Y. Liu and J. Merchan and M.B. Atkins},
year = {2024},
journal = {Annals of Oncology},
doi = {10.1016/j.annonc.2024.08.2338},
url = {https://doi.org/10.1016/j.annonc.2024.08.2338}
}RIS
TY - JOUR TI - Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma AU - N. Agarwal AU - J. Brugarolas AU - P. Ghatalia AU - S. George AU - J.B. Haanen AU - H. Gurney AU - R. Ravilla AU - A. Van der Veldt AU - B. Beuselinck AU - I. Pokataev AU - B.B.M. Suelmann AU - M.H. Tuthill AU - D. Vaena AU - F. Zagouri AU - J. Wu AU - R.F. Perini AU - Y. Liu AU - J. Merchan AU - M.B. Atkins PY - 2024 JO - Annals of Oncology DO - 10.1016/j.annonc.2024.08.2338 UR - https://doi.org/10.1016/j.annonc.2024.08.2338 ER -
APA
Agarwal, N., Brugarolas, J., Ghatalia, P., George, S., Haanen, J., Gurney, H., Ravilla, R., Veldt, A. V. D., Beuselinck, B., Pokataev, I., Suelmann, B., Tuthill, M., Vaena, D., Zagouri, F., Wu, J., Perini, R., Liu, Y., Merchan, J., & Atkins, M. (2024). Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma. Annals of Oncology. https://doi.org/10.1016/j.annonc.2024.08.2338
Source records
- crossref · retrieved 2026-11-10T20:07:51.519Z